Today we are pleased to announce a new audio interview with Andrew Kucharchuk, who is the CFO at OncBioMune Pharmaceuticals, Inc.. OncBioMune Pharmaceuticals, Inc. is a publicly traded company that trades in the U.S. under the symbol: OBMP
Interviewee: Andrew Kucharchuk
Interview Post Date: April 8, 2016
CHIEF FINANCIAL OFFICER, PRESIDENT, DIRECTOR
Andrew “Al” Kucharchuk is a graduate of Louisiana State and Tulane Universities Freeman School of Business, where he earned an MBA with a Finance Concentration. He currently serves as the Company’s Chief Financial Officer and oversees the business and administrative processes. In addition to these duties, Al also directs business development efforts including the expansion of
operations to accommodate increased research and clinical development. Al has assisted Dr. Head in the administration of the three contracts that have lead to the clinical studies for the Company’s lead product, ProscaVax™.
Mr. Kucharchuk is a member of Kappa Alpha Order fraternity. He lives in Baton Rouge with his wife Jessica and their sons Henry and Davis.
About OncBioMune Pharmaceuticals
OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary vaccine technology that is designed to stimulate the immune system to selectively attack cancer cells without harm to the patient. The vaccine technology has been proven safe through use in more than 300 patients without a single serious adverse event. Our lead product, ProscaVax™ for prostate cancer, is near conclusion of a Phase 1 trial funded by the Department of Defense Navy Cancer Vaccine Program. Based upon data showing ProscaVax is non-toxic and can lower PSA levels, we are moving ProscaVax into a Phase 2 trial for prostate cancer patients in the “Active Surveillance” category, an early stage of disease for which there are currently no treatments without significant morbidities. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs, including paclitaxel (Abraxane). OncBioMune is headquartered in Baton Rouge, LA.